Adverse effects on growth rates in rats caused by buprenorphine administration.
As a routine postoperative treatment, a single dose of buprenorphine was given to rats at a dose of 0.05 mg/kg subcutaneously. However, some rats developed abnormal secretions around the nose and mouth and some animals died 3-5 days after surgery and analgesic treatment. At autopsy a yellow fibrous mass was found in the stomach and intestines. Observations of animals given buprenorphine revealed an abnormal ingestion of bedding material. This caused a disturbance to normal digestion, with gastric distension, weight loss or decreased growth rate, constipation and occasionally death. In this study rats were monitored for 6 days following surgery and analgesic treatment. A comparison of growth rates was made between rats given saline and buprenorphine or nalbuphine and between animals kept on bedding or grid floors for the first 24h after treatment. Of the animals held on bedding, the buprenorphine-treated animals did not lose weight as the other animals did, but had on the other hand a decreased growth rate during the measuring period of 6 days after surgery. When denied access to bedding for the first 24 h after surgery, rats given saline or nalbuphine had a reduced weight gain over the first 24 h, similar to the groups held on bedding. Rats held on grid floors and given buprenorphine continued to gain weight for the first 24 h. From day 3, there was no significant difference between the groups, which all gained weight.
Jacobson
C
C
Laboratory Animal Department, AstraZeneca, R&D Lund, Sweden.
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects*; D000818:Animals; D002047:Buprenorphine / Q000008:administration & dosage / Q000009:adverse effects*; D006130:Growth Disorders / Q000139:chemically induced / Q000662:veterinary*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012376:Rodent Diseases / Q000139:chemically induced*; D015430:Weight Gain
D000701:Analgesics, Opioid; D002047:Buprenorphine